



## OPEN ACCESS

EDITED AND REVIEWED BY  
Michael Tovey,  
Svar Life Science, France

## \*CORRESPONDENCE

Thierry Dervieux  
✉ [tdervieux@prometheulabs.com](mailto:tdervieux@prometheulabs.com)

RECEIVED 07 February 2024

ACCEPTED 16 February 2024

PUBLISHED 27 February 2024

## CITATION

Spencer EA, Dubinsky MC, Kamm MA, Chaparro M, Gionchetti P, Rizzello F, Gisbert JP, Wright EK, Schulberg JD, Hamilton AL, McGovern DPB and Dervieux T (2024) Corrigendum: Poor prognostic factors of pharmacokinetic origin predict outcomes in inflammatory bowel disease patients treated with anti-tumor necrosis factor- $\alpha$ . *Front. Immunol.* 15:1383704. doi: 10.3389/fimmu.2024.1383704

## COPYRIGHT

© 2024 Spencer, Dubinsky, Kamm, Chaparro, Gionchetti, Rizzello, Gisbert, Wright, Schulberg, Hamilton, McGovern and Dervieux. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Corrigendum: Poor prognostic factors of pharmacokinetic origin predict outcomes in inflammatory bowel disease patients treated with anti-tumor necrosis factor- $\alpha$

Elizabeth A. Spencer<sup>1</sup>, Marla C. Dubinsky<sup>1</sup>, Michael A. Kamm<sup>2</sup>, Maria Chaparro<sup>3</sup>, Paolo Gionchetti<sup>4,5</sup>, Fernando Rizzello<sup>4,5</sup>, Javier P. Gisbert<sup>3</sup>, Emily K. Wright<sup>2</sup>, Julien D. Schulberg<sup>2</sup>, Amy L. Hamilton<sup>2</sup>, Dermot P. B. McGovern<sup>6</sup> and Thierry Dervieux<sup>7\*</sup>

<sup>1</sup>Division of Gastroenterology, Icahn School of Medicine Mount Sinai, New York, NY, United States, <sup>2</sup>St Vincent's Hospital and The University of Melbourne, Melbourne, VIC, Australia, <sup>3</sup>Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM) and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain, <sup>4</sup>IRCCS Azienda Ospedaliero-Universitaria di Bologna Italy, Bologna, Italy, <sup>5</sup>DIMEC University of Bologna-Italy, Bologna, Italy, <sup>6</sup>F. Widjaja Inflammatory Bowel Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States, <sup>7</sup>Research and Development, Prometheus Laboratories, San Diego, CA, United States

## KEYWORDS

drug response, tumor necrosis factor, clearance, inflammatory bowel disease, pharmacogenetic

## A Corrigendum on

Poor prognostic factors of pharmacokinetic origin predict outcomes in inflammatory bowel disease patients treated with anti-tumor necrosis factor- $\alpha$

By Spencer EA, Dubinsky MC, Kamm MA, Chaparro M, Gionchetti P, Rizzello F, Gisbert JP, Wright EK, Schulberg JD, Hamilton AL, McGovern DPB and Dervieux T (2024) *Front. Immunol.* 15:1342477. doi: 10.3389/fimmu.2024.1342477

In the published article, there was an error. In **Table 1**, the percentage of HLA DQA1\*05 carriage for “all cohort” was incorrect and was corrected to 40% (168/415).

In the Abstract, and Results, section 3.2. *Impact of PPF of PK origin on Immune response during treatment*, there was an error in the p value reported: “Overall, each incremental PPF of PK origin resulted in a 2-fold (OR=2.16, 95%CI: 1.7-2.7; p<0.11) higher likelihood of antidrug antibody formation”.

The corrected sentence appears below:

“Overall, each incremental PPF of PK origin resulted in a 2-fold (OR=2.16, 95%CI: 1.7-2.7;  $p<0.01$ ) higher likelihood of antidrug antibody formation”.

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.